Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical‑stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, has announced the pricing of its previously announced underwritten public offering of 6,400,000 American Depositary Shares (ADSs), each representing one ordinary share, €0.01 nominal value per share (each an ordinary share), of the Company, in the United States at an offering price of US$125 per ADS. The size of the offering was increased from the previously announced offering size of US$600 million ADSs.
Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili, Alison Haggerty, and Sandy Kugbei, with associates Isabelle Sawhney and Kan Ni.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
